Immunogen wants the world to know about its other antibody-drug conjugate clinical programs - beyond Genentech's T-DM1 - to let everyone know they are alive and kicking. It's CEO will get the word out at an analysts conference today and at scientific meetings later this year.
On parade our two compounds, IMGN859 and IMGN529, for non-hodkin's lymphoma and folate receptor bearing cancers, like breast or ovarian, respectively. Immunogen plans to file an IND with the FDA in mid-2011 for a non-hodgkins trial. IMGN529 will enter human testing in phase I trials for various cancers in early next year.
I believe that ADCs will be important cancer drugs going forward and it will be important to keep abreast of these trials as they progress.
Posted by Bruce Lehr Feb 25th 2011.